https://gne-7915inhibitor.com/....growth-and-developme
Few advancements in managing limited-stage SCLC (LS-SCLC) were made in years. We report here a phase 1/2 trial of concurrent chemoradiotherapy (CRT) and pembrolizumab. This single-center, open-label phase 1/2 study recruited grownups with LS-SCLC or other neuroendocrine tumors and great performance status (Eastern Cooperative Oncology Group ≤ 2). The primary end-point was security, as assessed by dose-limiting toxicities. Concurrent CRT consisted of etoposide and a platin with 45 Gy radiotherap
إعجاب
علق
شارك
